Type 1 Diabetes Mellitus (T1DM) is a chronic, progressive and serious
disease characterized by a destruction or failure of insulin-secreting
pancreatic beta cells, usually as a result of an autoimmune response.
The resulting insulin deficiency prevents insulin-sensitive cells from
carrying out essential glucose metabolism and leads to hyperglycemia
(high blood glucose levels).

As a result, immediate and lifelong treatment with exogenous insulin
therapy is initiated upon diagnosis of T1DM. Exogenous insulin has
remained the mainstay of T1DM therapy since it was used to treat the
first human patient in 1922.

Consequently, insulin products comprise the vast majority of the T1DM
market, which is largely monopolized by three big pharma players: Eli
Lilly, Novo Nordisk and Sanofi. However, insulin treatment regimens are
often inconvenient and are associated with undesirable side effects such
as hypoglycemia (low blood glucose levels) and weight gain.

In addition, there is a significant unmet need for more diversified
treatment options including therapies capable of altering the clinical
course of the pathological beta cell destruction and adjuvant therapies
capable of improving glycemic control and reducing insulin requirements.

Scope

- An introduction to T1DM, which includes classification, symptoms,
etiology, pathophysiology, co-morbidities and complications, diagnosis
and treatment

- An analysis of the leading insulin therapies in the current T1DM
marketed products landscape.

- An analysis of the pipeline for T1DM. This includes a breakdown of
pipeline molecules by stage of development, molecule type, route of
administration, molecular target and novelty. Trends in T1DM clinical
trial size, duration and failure rates, by molecule type and molecular
target are discussed. A comparative analysis of the most promising
pipeline molecules is also provided.

- Forecast projections for the T1DM market to 2021. An analysis is
provided for the global market and each of the eight major markets. The
forecast incorporates projected, low and high variance scenarios based
on treatment usage patterns and annual therapy costs in each of the
major markets.

- An analysis of strategic consolidations, including co-development and
licensing deals, within the T1DM indication.